nodes	percent_of_prediction	percent_of_DWPC	metapath
Topotecan—Topoisomerase Inhibitors—Epirubicin—thyroid cancer	0.292	0.519	CiPCiCtD
Topotecan—lung cancer—thyroid cancer	0.279	1	CtDrD
Topotecan—Topoisomerase Inhibitors—Doxorubicin—thyroid cancer	0.271	0.481	CiPCiCtD
Topotecan—ABCG2—Vandetanib—thyroid cancer	0.0392	0.365	CbGbCtD
Topotecan—ABCG2—Sorafenib—thyroid cancer	0.0236	0.22	CbGbCtD
Topotecan—ABCG2—Doxorubicin—thyroid cancer	0.0143	0.133	CbGbCtD
Topotecan—ABCB1—Sorafenib—thyroid cancer	0.00852	0.0792	CbGbCtD
Topotecan—CYP3A4—Vandetanib—thyroid cancer	0.00846	0.0788	CbGbCtD
Topotecan—ABCB1—Doxorubicin—thyroid cancer	0.00517	0.0481	CbGbCtD
Topotecan—CYP3A4—Sorafenib—thyroid cancer	0.0051	0.0475	CbGbCtD
Topotecan—CYP3A4—Doxorubicin—thyroid cancer	0.0031	0.0288	CbGbCtD
Topotecan—TOP1MT—thyroid gland—thyroid cancer	0.000798	0.171	CbGeAlD
Topotecan—TOP1MT—head—thyroid cancer	0.000708	0.152	CbGeAlD
Topotecan—TOP1—saliva-secreting gland—thyroid cancer	0.00069	0.148	CbGeAlD
Topotecan—TOP1—trachea—thyroid cancer	0.000532	0.114	CbGeAlD
Topotecan—TOP1MT—lymph node—thyroid cancer	0.000496	0.106	CbGeAlD
Topotecan—TOP1—thyroid gland—thyroid cancer	0.000421	0.0901	CbGeAlD
Topotecan—TOP1—lymph node—thyroid cancer	0.000261	0.056	CbGeAlD
Topotecan—ABCG2—saliva-secreting gland—thyroid cancer	0.000245	0.0524	CbGeAlD
Topotecan—Pelvic pain—Doxorubicin—thyroid cancer	0.000189	0.00415	CcSEcCtD
Topotecan—Infestation NOS—Sorafenib—thyroid cancer	0.000188	0.00413	CcSEcCtD
Topotecan—Infestation—Sorafenib—thyroid cancer	0.000188	0.00413	CcSEcCtD
Topotecan—Arthralgia—Vandetanib—thyroid cancer	0.000185	0.00407	CcSEcCtD
Topotecan—Chest pain—Vandetanib—thyroid cancer	0.000185	0.00407	CcSEcCtD
Topotecan—Neuropathy peripheral—Sorafenib—thyroid cancer	0.000184	0.00405	CcSEcCtD
Topotecan—Unspecified disorder of skin and subcutaneous tissue—Vandetanib—thyroid cancer	0.000184	0.00404	CcSEcCtD
Topotecan—Stomatitis—Sorafenib—thyroid cancer	0.000183	0.00402	CcSEcCtD
Topotecan—Neuralgia—Epirubicin—thyroid cancer	0.000179	0.00393	CcSEcCtD
Topotecan—Hepatobiliary disease—Sorafenib—thyroid cancer	0.000178	0.0039	CcSEcCtD
Topotecan—Epistaxis—Sorafenib—thyroid cancer	0.000177	0.00389	CcSEcCtD
Topotecan—Infection—Vandetanib—thyroid cancer	0.000176	0.00388	CcSEcCtD
Topotecan—Lung disorder—Epirubicin—thyroid cancer	0.000175	0.00385	CcSEcCtD
Topotecan—Nervous system disorder—Vandetanib—thyroid cancer	0.000174	0.00383	CcSEcCtD
Topotecan—Thrombocytopenia—Vandetanib—thyroid cancer	0.000174	0.00382	CcSEcCtD
Topotecan—Skin disorder—Vandetanib—thyroid cancer	0.000172	0.00379	CcSEcCtD
Topotecan—Haemoglobin—Sorafenib—thyroid cancer	0.000169	0.00373	CcSEcCtD
Topotecan—Haemorrhage—Sorafenib—thyroid cancer	0.000169	0.00371	CcSEcCtD
Topotecan—Neuralgia—Doxorubicin—thyroid cancer	0.000165	0.00363	CcSEcCtD
Topotecan—Lung disorder—Doxorubicin—thyroid cancer	0.000162	0.00357	CcSEcCtD
Topotecan—Rash erythematous—Epirubicin—thyroid cancer	0.000162	0.00356	CcSEcCtD
Topotecan—Pleural effusion—Epirubicin—thyroid cancer	0.000162	0.00356	CcSEcCtD
Topotecan—Musculoskeletal discomfort—Vandetanib—thyroid cancer	0.000162	0.00356	CcSEcCtD
Topotecan—Paraesthesia—Vandetanib—thyroid cancer	0.000159	0.00351	CcSEcCtD
Topotecan—Dyspnoea—Vandetanib—thyroid cancer	0.000158	0.00348	CcSEcCtD
Topotecan—Dyspepsia—Vandetanib—thyroid cancer	0.000156	0.00344	CcSEcCtD
Topotecan—Decreased appetite—Vandetanib—thyroid cancer	0.000154	0.00339	CcSEcCtD
Topotecan—Gastrointestinal disorder—Vandetanib—thyroid cancer	0.000153	0.00337	CcSEcCtD
Topotecan—Fatigue—Vandetanib—thyroid cancer	0.000153	0.00337	CcSEcCtD
Topotecan—Angiopathy—Sorafenib—thyroid cancer	0.000153	0.00336	CcSEcCtD
Topotecan—Immune system disorder—Sorafenib—thyroid cancer	0.000152	0.00335	CcSEcCtD
Topotecan—Rigors—Epirubicin—thyroid cancer	0.000152	0.00334	CcSEcCtD
Topotecan—Mediastinal disorder—Sorafenib—thyroid cancer	0.000152	0.00334	CcSEcCtD
Topotecan—Constipation—Vandetanib—thyroid cancer	0.000152	0.00334	CcSEcCtD
Topotecan—Pain—Vandetanib—thyroid cancer	0.000152	0.00334	CcSEcCtD
Topotecan—Pleural effusion—Doxorubicin—thyroid cancer	0.00015	0.0033	CcSEcCtD
Topotecan—Rash erythematous—Doxorubicin—thyroid cancer	0.00015	0.0033	CcSEcCtD
Topotecan—ABCG2—thyroid gland—thyroid cancer	0.000149	0.032	CbGeAlD
Topotecan—Alopecia—Sorafenib—thyroid cancer	0.000149	0.00328	CcSEcCtD
Topotecan—Malnutrition—Sorafenib—thyroid cancer	0.000147	0.00323	CcSEcCtD
Topotecan—Gastrointestinal pain—Vandetanib—thyroid cancer	0.000145	0.00319	CcSEcCtD
Topotecan—Extravasation—Epirubicin—thyroid cancer	0.000142	0.00313	CcSEcCtD
Topotecan—Muscle spasms—Sorafenib—thyroid cancer	0.000141	0.0031	CcSEcCtD
Topotecan—Rigors—Doxorubicin—thyroid cancer	0.000141	0.00309	CcSEcCtD
Topotecan—Abdominal pain—Vandetanib—thyroid cancer	0.00014	0.00309	CcSEcCtD
Topotecan—Body temperature increased—Vandetanib—thyroid cancer	0.00014	0.00309	CcSEcCtD
Topotecan—Hyperbilirubinaemia—Epirubicin—thyroid cancer	0.000136	0.003	CcSEcCtD
Topotecan—Anaemia—Sorafenib—thyroid cancer	0.000136	0.00298	CcSEcCtD
Topotecan—Angioedema—Sorafenib—thyroid cancer	0.000134	0.00295	CcSEcCtD
Topotecan—Extravasation—Doxorubicin—thyroid cancer	0.000132	0.00289	CcSEcCtD
Topotecan—Leukopenia—Sorafenib—thyroid cancer	0.000131	0.00289	CcSEcCtD
Topotecan—Blood bilirubin increased—Epirubicin—thyroid cancer	0.000131	0.00288	CcSEcCtD
Topotecan—Bone pain—Epirubicin—thyroid cancer	0.00013	0.00285	CcSEcCtD
Topotecan—Cough—Sorafenib—thyroid cancer	0.000128	0.00282	CcSEcCtD
Topotecan—Asthenia—Vandetanib—thyroid cancer	0.000127	0.0028	CcSEcCtD
Topotecan—Hyperbilirubinaemia—Doxorubicin—thyroid cancer	0.000126	0.00278	CcSEcCtD
Topotecan—Pruritus—Vandetanib—thyroid cancer	0.000126	0.00276	CcSEcCtD
Topotecan—Myalgia—Sorafenib—thyroid cancer	0.000125	0.00275	CcSEcCtD
Topotecan—Arthralgia—Sorafenib—thyroid cancer	0.000125	0.00275	CcSEcCtD
Topotecan—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—thyroid cancer	0.000124	0.00273	CcSEcCtD
Topotecan—Pulmonary embolism—Epirubicin—thyroid cancer	0.000124	0.00273	CcSEcCtD
Topotecan—Diarrhoea—Vandetanib—thyroid cancer	0.000121	0.00267	CcSEcCtD
Topotecan—Blood bilirubin increased—Doxorubicin—thyroid cancer	0.000121	0.00267	CcSEcCtD
Topotecan—Bone pain—Doxorubicin—thyroid cancer	0.00012	0.00263	CcSEcCtD
Topotecan—Anaphylactic shock—Sorafenib—thyroid cancer	0.00012	0.00263	CcSEcCtD
Topotecan—Colitis—Epirubicin—thyroid cancer	0.000119	0.00262	CcSEcCtD
Topotecan—Infection—Sorafenib—thyroid cancer	0.000119	0.00262	CcSEcCtD
Topotecan—Nervous system disorder—Sorafenib—thyroid cancer	0.000117	0.00258	CcSEcCtD
Topotecan—Dizziness—Vandetanib—thyroid cancer	0.000117	0.00258	CcSEcCtD
Topotecan—Thrombocytopenia—Sorafenib—thyroid cancer	0.000117	0.00258	CcSEcCtD
Topotecan—Neuropathy—Epirubicin—thyroid cancer	0.000116	0.00256	CcSEcCtD
Topotecan—Skin disorder—Sorafenib—thyroid cancer	0.000116	0.00256	CcSEcCtD
Topotecan—Pulmonary embolism—Doxorubicin—thyroid cancer	0.000115	0.00252	CcSEcCtD
Topotecan—Anorexia—Sorafenib—thyroid cancer	0.000114	0.00251	CcSEcCtD
Topotecan—Vomiting—Vandetanib—thyroid cancer	0.000113	0.00248	CcSEcCtD
Topotecan—Rash maculo-papular—Epirubicin—thyroid cancer	0.000113	0.00248	CcSEcCtD
Topotecan—Neoplasm—Epirubicin—thyroid cancer	0.000112	0.00247	CcSEcCtD
Topotecan—Rash—Vandetanib—thyroid cancer	0.000112	0.00246	CcSEcCtD
Topotecan—Dermatitis—Vandetanib—thyroid cancer	0.000112	0.00246	CcSEcCtD
Topotecan—Headache—Vandetanib—thyroid cancer	0.000111	0.00245	CcSEcCtD
Topotecan—Colitis—Doxorubicin—thyroid cancer	0.00011	0.00242	CcSEcCtD
Topotecan—Musculoskeletal discomfort—Sorafenib—thyroid cancer	0.000109	0.0024	CcSEcCtD
Topotecan—Neuropathy—Doxorubicin—thyroid cancer	0.000108	0.00237	CcSEcCtD
Topotecan—Sepsis—Epirubicin—thyroid cancer	0.000108	0.00237	CcSEcCtD
Topotecan—Dyspnoea—Sorafenib—thyroid cancer	0.000107	0.00235	CcSEcCtD
Topotecan—Nausea—Vandetanib—thyroid cancer	0.000105	0.00232	CcSEcCtD
Topotecan—Dyspepsia—Sorafenib—thyroid cancer	0.000105	0.00232	CcSEcCtD
Topotecan—Rash maculo-papular—Doxorubicin—thyroid cancer	0.000104	0.00229	CcSEcCtD
Topotecan—Decreased appetite—Sorafenib—thyroid cancer	0.000104	0.00229	CcSEcCtD
Topotecan—Neoplasm—Doxorubicin—thyroid cancer	0.000104	0.00228	CcSEcCtD
Topotecan—Gastrointestinal disorder—Sorafenib—thyroid cancer	0.000103	0.00227	CcSEcCtD
Topotecan—Fatigue—Sorafenib—thyroid cancer	0.000103	0.00227	CcSEcCtD
Topotecan—Pain—Sorafenib—thyroid cancer	0.000102	0.00225	CcSEcCtD
Topotecan—Constipation—Sorafenib—thyroid cancer	0.000102	0.00225	CcSEcCtD
Topotecan—Sepsis—Doxorubicin—thyroid cancer	9.96e-05	0.00219	CcSEcCtD
Topotecan—Gastrointestinal pain—Sorafenib—thyroid cancer	9.8e-05	0.00215	CcSEcCtD
Topotecan—Urticaria—Sorafenib—thyroid cancer	9.52e-05	0.00209	CcSEcCtD
Topotecan—Abdominal pain—Sorafenib—thyroid cancer	9.47e-05	0.00208	CcSEcCtD
Topotecan—Body temperature increased—Sorafenib—thyroid cancer	9.47e-05	0.00208	CcSEcCtD
Topotecan—Dermatitis bullous—Epirubicin—thyroid cancer	9.42e-05	0.00207	CcSEcCtD
Topotecan—Anaphylactoid reaction—Epirubicin—thyroid cancer	9.31e-05	0.00205	CcSEcCtD
Topotecan—ABCB1—trachea—thyroid cancer	9.31e-05	0.0199	CbGeAlD
Topotecan—ABCG2—lymph node—thyroid cancer	9.27e-05	0.0199	CbGeAlD
Topotecan—Lethargy—Epirubicin—thyroid cancer	9.19e-05	0.00202	CcSEcCtD
Topotecan—Hypersensitivity—Sorafenib—thyroid cancer	8.83e-05	0.00194	CcSEcCtD
Topotecan—Dermatitis bullous—Doxorubicin—thyroid cancer	8.72e-05	0.00192	CcSEcCtD
Topotecan—Anaphylactoid reaction—Doxorubicin—thyroid cancer	8.61e-05	0.00189	CcSEcCtD
Topotecan—Asthenia—Sorafenib—thyroid cancer	8.59e-05	0.00189	CcSEcCtD
Topotecan—Cardiac arrest—Epirubicin—thyroid cancer	8.56e-05	0.00188	CcSEcCtD
Topotecan—Lethargy—Doxorubicin—thyroid cancer	8.5e-05	0.00187	CcSEcCtD
Topotecan—Pruritus—Sorafenib—thyroid cancer	8.47e-05	0.00186	CcSEcCtD
Topotecan—Diarrhoea—Sorafenib—thyroid cancer	8.2e-05	0.0018	CcSEcCtD
Topotecan—Aspartate aminotransferase increased—Epirubicin—thyroid cancer	8.11e-05	0.00178	CcSEcCtD
Topotecan—Alanine aminotransferase increased—Epirubicin—thyroid cancer	7.94e-05	0.00175	CcSEcCtD
Topotecan—Cardiac arrest—Doxorubicin—thyroid cancer	7.92e-05	0.00174	CcSEcCtD
Topotecan—Dizziness—Sorafenib—thyroid cancer	7.92e-05	0.00174	CcSEcCtD
Topotecan—Vomiting—Sorafenib—thyroid cancer	7.62e-05	0.00167	CcSEcCtD
Topotecan—Rash—Sorafenib—thyroid cancer	7.55e-05	0.00166	CcSEcCtD
Topotecan—Dermatitis—Sorafenib—thyroid cancer	7.55e-05	0.00166	CcSEcCtD
Topotecan—Aspartate aminotransferase increased—Doxorubicin—thyroid cancer	7.5e-05	0.00165	CcSEcCtD
Topotecan—Headache—Sorafenib—thyroid cancer	7.5e-05	0.00165	CcSEcCtD
Topotecan—Pancytopenia—Epirubicin—thyroid cancer	7.39e-05	0.00163	CcSEcCtD
Topotecan—ABCB1—thyroid gland—thyroid cancer	7.36e-05	0.0158	CbGeAlD
Topotecan—Alanine aminotransferase increased—Doxorubicin—thyroid cancer	7.35e-05	0.00162	CcSEcCtD
Topotecan—Neutropenia—Epirubicin—thyroid cancer	7.28e-05	0.0016	CcSEcCtD
Topotecan—Nausea—Sorafenib—thyroid cancer	7.12e-05	0.00156	CcSEcCtD
Topotecan—Weight increased—Epirubicin—thyroid cancer	7.08e-05	0.00156	CcSEcCtD
Topotecan—Pneumonia—Epirubicin—thyroid cancer	6.98e-05	0.00153	CcSEcCtD
Topotecan—Infestation—Epirubicin—thyroid cancer	6.94e-05	0.00153	CcSEcCtD
Topotecan—Infestation NOS—Epirubicin—thyroid cancer	6.94e-05	0.00153	CcSEcCtD
Topotecan—Pancytopenia—Doxorubicin—thyroid cancer	6.84e-05	0.0015	CcSEcCtD
Topotecan—Neuropathy peripheral—Epirubicin—thyroid cancer	6.8e-05	0.0015	CcSEcCtD
Topotecan—Stomatitis—Epirubicin—thyroid cancer	6.77e-05	0.00149	CcSEcCtD
Topotecan—Neutropenia—Doxorubicin—thyroid cancer	6.74e-05	0.00148	CcSEcCtD
Topotecan—Sweating—Epirubicin—thyroid cancer	6.65e-05	0.00146	CcSEcCtD
Topotecan—Hepatobiliary disease—Epirubicin—thyroid cancer	6.56e-05	0.00144	CcSEcCtD
Topotecan—Weight increased—Doxorubicin—thyroid cancer	6.56e-05	0.00144	CcSEcCtD
Topotecan—Epistaxis—Epirubicin—thyroid cancer	6.55e-05	0.00144	CcSEcCtD
Topotecan—ABCB1—head—thyroid cancer	6.53e-05	0.014	CbGeAlD
Topotecan—Pneumonia—Doxorubicin—thyroid cancer	6.46e-05	0.00142	CcSEcCtD
Topotecan—Infestation NOS—Doxorubicin—thyroid cancer	6.42e-05	0.00141	CcSEcCtD
Topotecan—Infestation—Doxorubicin—thyroid cancer	6.42e-05	0.00141	CcSEcCtD
Topotecan—Neuropathy peripheral—Doxorubicin—thyroid cancer	6.3e-05	0.00138	CcSEcCtD
Topotecan—Haemoglobin—Epirubicin—thyroid cancer	6.26e-05	0.00138	CcSEcCtD
Topotecan—Stomatitis—Doxorubicin—thyroid cancer	6.26e-05	0.00138	CcSEcCtD
Topotecan—Rhinitis—Epirubicin—thyroid cancer	6.25e-05	0.00137	CcSEcCtD
Topotecan—Haemorrhage—Epirubicin—thyroid cancer	6.23e-05	0.00137	CcSEcCtD
Topotecan—Hypoaesthesia—Epirubicin—thyroid cancer	6.2e-05	0.00136	CcSEcCtD
Topotecan—Pharyngitis—Epirubicin—thyroid cancer	6.18e-05	0.00136	CcSEcCtD
Topotecan—Sweating—Doxorubicin—thyroid cancer	6.16e-05	0.00135	CcSEcCtD
Topotecan—Hepatobiliary disease—Doxorubicin—thyroid cancer	6.07e-05	0.00134	CcSEcCtD
Topotecan—Epistaxis—Doxorubicin—thyroid cancer	6.06e-05	0.00133	CcSEcCtD
Topotecan—Haemoglobin—Doxorubicin—thyroid cancer	5.79e-05	0.00127	CcSEcCtD
Topotecan—Rhinitis—Doxorubicin—thyroid cancer	5.78e-05	0.00127	CcSEcCtD
Topotecan—Haemorrhage—Doxorubicin—thyroid cancer	5.77e-05	0.00127	CcSEcCtD
Topotecan—Hypoaesthesia—Doxorubicin—thyroid cancer	5.74e-05	0.00126	CcSEcCtD
Topotecan—Pharyngitis—Doxorubicin—thyroid cancer	5.72e-05	0.00126	CcSEcCtD
Topotecan—Angiopathy—Epirubicin—thyroid cancer	5.65e-05	0.00124	CcSEcCtD
Topotecan—Immune system disorder—Epirubicin—thyroid cancer	5.63e-05	0.00124	CcSEcCtD
Topotecan—Mediastinal disorder—Epirubicin—thyroid cancer	5.62e-05	0.00123	CcSEcCtD
Topotecan—Chills—Epirubicin—thyroid cancer	5.59e-05	0.00123	CcSEcCtD
Topotecan—Alopecia—Epirubicin—thyroid cancer	5.51e-05	0.00121	CcSEcCtD
Topotecan—Malnutrition—Epirubicin—thyroid cancer	5.42e-05	0.00119	CcSEcCtD
Topotecan—Back pain—Epirubicin—thyroid cancer	5.25e-05	0.00115	CcSEcCtD
Topotecan—Angiopathy—Doxorubicin—thyroid cancer	5.23e-05	0.00115	CcSEcCtD
Topotecan—Muscle spasms—Epirubicin—thyroid cancer	5.21e-05	0.00115	CcSEcCtD
Topotecan—Immune system disorder—Doxorubicin—thyroid cancer	5.21e-05	0.00114	CcSEcCtD
Topotecan—Mediastinal disorder—Doxorubicin—thyroid cancer	5.2e-05	0.00114	CcSEcCtD
Topotecan—Chills—Doxorubicin—thyroid cancer	5.17e-05	0.00114	CcSEcCtD
Topotecan—Alopecia—Doxorubicin—thyroid cancer	5.09e-05	0.00112	CcSEcCtD
Topotecan—Ill-defined disorder—Epirubicin—thyroid cancer	5.03e-05	0.00111	CcSEcCtD
Topotecan—Malnutrition—Doxorubicin—thyroid cancer	5.02e-05	0.0011	CcSEcCtD
Topotecan—Anaemia—Epirubicin—thyroid cancer	5.01e-05	0.0011	CcSEcCtD
Topotecan—Malaise—Epirubicin—thyroid cancer	4.89e-05	0.00108	CcSEcCtD
Topotecan—Leukopenia—Epirubicin—thyroid cancer	4.86e-05	0.00107	CcSEcCtD
Topotecan—Back pain—Doxorubicin—thyroid cancer	4.85e-05	0.00107	CcSEcCtD
Topotecan—Muscle spasms—Doxorubicin—thyroid cancer	4.83e-05	0.00106	CcSEcCtD
Topotecan—Cough—Epirubicin—thyroid cancer	4.73e-05	0.00104	CcSEcCtD
Topotecan—Ill-defined disorder—Doxorubicin—thyroid cancer	4.66e-05	0.00102	CcSEcCtD
Topotecan—Anaemia—Doxorubicin—thyroid cancer	4.64e-05	0.00102	CcSEcCtD
Topotecan—Arthralgia—Epirubicin—thyroid cancer	4.62e-05	0.00102	CcSEcCtD
Topotecan—Chest pain—Epirubicin—thyroid cancer	4.62e-05	0.00102	CcSEcCtD
Topotecan—Myalgia—Epirubicin—thyroid cancer	4.62e-05	0.00102	CcSEcCtD
Topotecan—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—thyroid cancer	4.59e-05	0.00101	CcSEcCtD
Topotecan—ABCB1—lymph node—thyroid cancer	4.57e-05	0.00979	CbGeAlD
Topotecan—Discomfort—Epirubicin—thyroid cancer	4.56e-05	0.001	CcSEcCtD
Topotecan—Malaise—Doxorubicin—thyroid cancer	4.53e-05	0.000995	CcSEcCtD
Topotecan—Leukopenia—Doxorubicin—thyroid cancer	4.49e-05	0.000988	CcSEcCtD
Topotecan—Anaphylactic shock—Epirubicin—thyroid cancer	4.43e-05	0.000973	CcSEcCtD
Topotecan—Infection—Epirubicin—thyroid cancer	4.4e-05	0.000967	CcSEcCtD
Topotecan—Cough—Doxorubicin—thyroid cancer	4.38e-05	0.000963	CcSEcCtD
Topotecan—Nervous system disorder—Epirubicin—thyroid cancer	4.34e-05	0.000954	CcSEcCtD
Topotecan—Thrombocytopenia—Epirubicin—thyroid cancer	4.33e-05	0.000953	CcSEcCtD
Topotecan—Skin disorder—Epirubicin—thyroid cancer	4.3e-05	0.000945	CcSEcCtD
Topotecan—Hyperhidrosis—Epirubicin—thyroid cancer	4.28e-05	0.000941	CcSEcCtD
Topotecan—Myalgia—Doxorubicin—thyroid cancer	4.27e-05	0.000939	CcSEcCtD
Topotecan—Arthralgia—Doxorubicin—thyroid cancer	4.27e-05	0.000939	CcSEcCtD
Topotecan—Chest pain—Doxorubicin—thyroid cancer	4.27e-05	0.000939	CcSEcCtD
Topotecan—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—thyroid cancer	4.24e-05	0.000933	CcSEcCtD
Topotecan—Discomfort—Doxorubicin—thyroid cancer	4.22e-05	0.000928	CcSEcCtD
Topotecan—Anorexia—Epirubicin—thyroid cancer	4.22e-05	0.000928	CcSEcCtD
Topotecan—Anaphylactic shock—Doxorubicin—thyroid cancer	4.1e-05	0.0009	CcSEcCtD
Topotecan—Infection—Doxorubicin—thyroid cancer	4.07e-05	0.000895	CcSEcCtD
Topotecan—Musculoskeletal discomfort—Epirubicin—thyroid cancer	4.03e-05	0.000887	CcSEcCtD
Topotecan—Nervous system disorder—Doxorubicin—thyroid cancer	4.02e-05	0.000883	CcSEcCtD
Topotecan—Thrombocytopenia—Doxorubicin—thyroid cancer	4.01e-05	0.000882	CcSEcCtD
Topotecan—Skin disorder—Doxorubicin—thyroid cancer	3.98e-05	0.000875	CcSEcCtD
Topotecan—Paraesthesia—Epirubicin—thyroid cancer	3.98e-05	0.000874	CcSEcCtD
Topotecan—Hyperhidrosis—Doxorubicin—thyroid cancer	3.96e-05	0.00087	CcSEcCtD
Topotecan—Dyspnoea—Epirubicin—thyroid cancer	3.95e-05	0.000868	CcSEcCtD
Topotecan—Anorexia—Doxorubicin—thyroid cancer	3.9e-05	0.000858	CcSEcCtD
Topotecan—Dyspepsia—Epirubicin—thyroid cancer	3.9e-05	0.000857	CcSEcCtD
Topotecan—Decreased appetite—Epirubicin—thyroid cancer	3.85e-05	0.000846	CcSEcCtD
Topotecan—Gastrointestinal disorder—Epirubicin—thyroid cancer	3.82e-05	0.00084	CcSEcCtD
Topotecan—Fatigue—Epirubicin—thyroid cancer	3.82e-05	0.000839	CcSEcCtD
Topotecan—Pain—Epirubicin—thyroid cancer	3.79e-05	0.000832	CcSEcCtD
Topotecan—Constipation—Epirubicin—thyroid cancer	3.79e-05	0.000832	CcSEcCtD
Topotecan—Musculoskeletal discomfort—Doxorubicin—thyroid cancer	3.73e-05	0.00082	CcSEcCtD
Topotecan—Paraesthesia—Doxorubicin—thyroid cancer	3.68e-05	0.000809	CcSEcCtD
Topotecan—Dyspnoea—Doxorubicin—thyroid cancer	3.65e-05	0.000803	CcSEcCtD
Topotecan—Feeling abnormal—Epirubicin—thyroid cancer	3.65e-05	0.000802	CcSEcCtD
Topotecan—Gastrointestinal pain—Epirubicin—thyroid cancer	3.62e-05	0.000796	CcSEcCtD
Topotecan—Dyspepsia—Doxorubicin—thyroid cancer	3.61e-05	0.000793	CcSEcCtD
Topotecan—Decreased appetite—Doxorubicin—thyroid cancer	3.56e-05	0.000783	CcSEcCtD
Topotecan—Gastrointestinal disorder—Doxorubicin—thyroid cancer	3.54e-05	0.000777	CcSEcCtD
Topotecan—Fatigue—Doxorubicin—thyroid cancer	3.53e-05	0.000776	CcSEcCtD
Topotecan—Urticaria—Epirubicin—thyroid cancer	3.52e-05	0.000773	CcSEcCtD
Topotecan—Constipation—Doxorubicin—thyroid cancer	3.5e-05	0.00077	CcSEcCtD
Topotecan—Pain—Doxorubicin—thyroid cancer	3.5e-05	0.00077	CcSEcCtD
Topotecan—Abdominal pain—Epirubicin—thyroid cancer	3.5e-05	0.000769	CcSEcCtD
Topotecan—Body temperature increased—Epirubicin—thyroid cancer	3.5e-05	0.000769	CcSEcCtD
Topotecan—Feeling abnormal—Doxorubicin—thyroid cancer	3.38e-05	0.000742	CcSEcCtD
Topotecan—Gastrointestinal pain—Doxorubicin—thyroid cancer	3.35e-05	0.000736	CcSEcCtD
Topotecan—Hypersensitivity—Epirubicin—thyroid cancer	3.26e-05	0.000717	CcSEcCtD
Topotecan—Urticaria—Doxorubicin—thyroid cancer	3.25e-05	0.000715	CcSEcCtD
Topotecan—Abdominal pain—Doxorubicin—thyroid cancer	3.24e-05	0.000712	CcSEcCtD
Topotecan—Body temperature increased—Doxorubicin—thyroid cancer	3.24e-05	0.000712	CcSEcCtD
Topotecan—Asthenia—Epirubicin—thyroid cancer	3.18e-05	0.000698	CcSEcCtD
Topotecan—Pruritus—Epirubicin—thyroid cancer	3.13e-05	0.000688	CcSEcCtD
Topotecan—Diarrhoea—Epirubicin—thyroid cancer	3.03e-05	0.000666	CcSEcCtD
Topotecan—Hypersensitivity—Doxorubicin—thyroid cancer	3.02e-05	0.000663	CcSEcCtD
Topotecan—Asthenia—Doxorubicin—thyroid cancer	2.94e-05	0.000646	CcSEcCtD
Topotecan—Dizziness—Epirubicin—thyroid cancer	2.93e-05	0.000644	CcSEcCtD
Topotecan—Pruritus—Doxorubicin—thyroid cancer	2.9e-05	0.000637	CcSEcCtD
Topotecan—Vomiting—Epirubicin—thyroid cancer	2.81e-05	0.000619	CcSEcCtD
Topotecan—Diarrhoea—Doxorubicin—thyroid cancer	2.8e-05	0.000616	CcSEcCtD
Topotecan—Rash—Epirubicin—thyroid cancer	2.79e-05	0.000614	CcSEcCtD
Topotecan—Dermatitis—Epirubicin—thyroid cancer	2.79e-05	0.000613	CcSEcCtD
Topotecan—Headache—Epirubicin—thyroid cancer	2.77e-05	0.00061	CcSEcCtD
Topotecan—Dizziness—Doxorubicin—thyroid cancer	2.71e-05	0.000595	CcSEcCtD
Topotecan—Nausea—Epirubicin—thyroid cancer	2.63e-05	0.000578	CcSEcCtD
Topotecan—Vomiting—Doxorubicin—thyroid cancer	2.6e-05	0.000573	CcSEcCtD
Topotecan—Rash—Doxorubicin—thyroid cancer	2.58e-05	0.000568	CcSEcCtD
Topotecan—Dermatitis—Doxorubicin—thyroid cancer	2.58e-05	0.000567	CcSEcCtD
Topotecan—Headache—Doxorubicin—thyroid cancer	2.57e-05	0.000564	CcSEcCtD
Topotecan—Nausea—Doxorubicin—thyroid cancer	2.43e-05	0.000535	CcSEcCtD
